Jiao Y Y, Ubrich N, Hoffart V, Marchand-Arvier M, Vigneron C, Hoffman M, Maincent P
Laboratoire de Pharmacie Galénique et Biopharmacie, Faculté de Pharmacie, 5, rue Albert Lebrun, B.P. 403, 54001 Nancy, France.
Drug Dev Ind Pharm. 2002 Sep;28(8):1033-41. doi: 10.1081/ddc-120014740.
Microparticles containing heparin were prepared by a water-in-oil-in-water emulsification and evaporation process with pure or blends of biodegradable (poly-epsilon-caprolactone and poly(D,L-lactic-co-glycolic acid)) and of positively-charged non-biodegradable (Eudragit RS and RL) polymers. The influence of polymers and some excipients (gelatin A and B, NaCl) on the particle size, the morphology, the heparin encapsulation rate as well as the in vitro drug release was investigated. The diameter of the microparticles prepared with the various polymers ranged from 80 to 130 microns and was found to increase significantly with the addition of gelatin A into the internal aqueous phase. Microparticles prepared with Eudragit RS and RL exhibited higher drug entrapment efficiency (49 and 80% respectively) but lower drug release within 24 h (17 and 3.5% respectively) than those prepared with PCL and PLAGA. The use of blends of two polymers in the organic phase was found to modify the drug entrapment as well as the heparin release kinetics compared with microparticles prepared with a single polymer. In addition, microparticles prepared with gelatin A showed higher entrapment efficiency, but a significant initial burst effect was observed during the heparin release. The in vitro biological activity of heparin released from the formulations affording a suitable drug release has been tested by measuring the anti-Xa activity by a colorimetric assay with a chromogenic substrate. The results confirmed that heparin remained unaltered after the entrapment process.
通过水包油包水乳化蒸发工艺,使用可生物降解的(聚ε-己内酯和聚(D,L-乳酸-乙醇酸共聚物))以及带正电荷的不可生物降解的(Eudragit RS和RL)聚合物的纯品或混合物制备了含肝素的微粒。研究了聚合物和一些辅料(明胶A和B、氯化钠)对粒径、形态、肝素包封率以及体外药物释放的影响。用各种聚合物制备的微粒直径在80至130微米之间,并且发现随着在内部水相中加入明胶A,粒径显著增加。与用聚己内酯(PCL)和聚乳酸-乙醇酸共聚物(PLAGA)制备的微粒相比,用Eudragit RS和RL制备的微粒表现出更高的药物包封效率(分别为49%和80%),但在24小时内药物释放较低(分别为17%和3.5%)。与用单一聚合物制备的微粒相比,发现在有机相中使用两种聚合物的混合物会改变药物包封以及肝素释放动力学。此外,用明胶A制备的微粒表现出更高的包封效率,但在肝素释放过程中观察到显著的初始突释效应。通过使用显色底物的比色法测量抗Xa活性,测试了从提供合适药物释放的制剂中释放的肝素的体外生物活性。结果证实肝素在包封过程后保持不变。